Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
dispersible of praziquantel · 1 trial · 1 indication
AUC0-inf is the area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time. AUC0-inf, adj was defined as the AUC0-inf adjusted for the actual administered dose of L-PZQ.
| Arm | Type | Description |
|---|---|---|
| Sequence A-B-C1-D1 | EXPERIMENTAL | - |
| Sequence A-B-C1-D2 | EXPERIMENTAL | - |
| Sequence A-B-C2-D1 | EXPERIMENTAL | - |
| Sequence A-B-C2-D2 | EXPERIMENTAL | - |
| Sequence A-B-D1-C1 | EXPERIMENTAL | - |
| Sequence A-B-D2-C1 | EXPERIMENTAL | - |
| Sequence A-B-D1-C2 | EXPERIMENTAL | - |
| Sequence A-B-D2-C2 | EXPERIMENTAL | - |
| Sequence B-A-C1-D1 | EXPERIMENTAL | - |
| Sequence B-A-C1-D2 | EXPERIMENTAL | - |
| Sequence B-A-C2-D1 | EXPERIMENTAL | - |
| Sequence B-A-C2-D2 | EXPERIMENTAL | - |
| Sequence B-A-D1-C1 | EXPERIMENTAL | - |
| Sequence B-A-D2-C1 | EXPERIMENTAL | - |
| Sequence B-A-D1-C2 | EXPERIMENTAL | - |
| Sequence B-A-D2-C2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Oral dispersible tablet of praziquantel (ODT-PZQ) | DRUG | Treatment A (test): ODT-PZQ (MSC1028703A) at a single dose of 40 milligram per kilogram (mg/kg) orally dispersed in water after meal. |
| Cysticide | DRUG | Treatment B (reference): Cysticide tablet at a single dose of 40 mg/kg will be given with water orally after a meal. |
| ODT-PZQ | DRUG | Treatment C1 (test): ODT-PZQ (MSC1028703A) at a single dose of 20 mg/kg orally dispersed in water after a meal. |
Inclusion Criteria: * Healthy males 18-55 years of age (inclusive at screening) * Male subjects with partners of childbearing potential must have had a vasectomy or use acceptable methods of birth control (that is, condoms) and not donate sperm during, and until 90 days after the last dose of the t...
Dispersible praziquantel is an investigational small molecule being studied in healthy volunteers. It is a dispersible tablet formulation of praziquantel, an antiparasitic drug. The drug is currently in Phase 1 clinical development, and its use is being evaluated in healthy subjects to assess its bioavailability.
Dispersible praziquantel is being developed by Merck & Company, Inc., which trades under the ticker symbol MRK. The company is conducting clinical trials to evaluate the drug's properties in healthy volunteers.
Dispersible praziquantel is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied in a completed Phase 1 trial involving healthy volunteers.
Dispersible praziquantel has one completed clinical trial, NCT02325713, titled 'Relative Bioavailability Trial of Oral Dispersible Praziquantel Tablets in Healthy Volunteers.' This Phase 1 study enrolled 32 healthy male participants in Germany and was a controlled, randomized trial.
Dispersible praziquantel is a formulation of praziquantel, an antiparasitic medication. It is designed as a dispersible tablet for oral administration. The drug is being studied in healthy volunteers to evaluate its relative bioavailability compared to other forms.